Keywords
Lambert-eaton myasthenic syndrome; Small cell lung cancer
Introduction
Lambert-Eaton myasthenic syndrome (LEMS) is a rare presynaptic
autoimmune disease of the neuromuscular transmission with an
incidence of 0.5 per million and a prevalence of 3.4 per million [1]. It
Is mediated by antibodies directed mainly against P/Q type of voltagegated
calcium channels (VGCC) which are detected in about 85%-90%
of the patients [2]. A tumor, mainly a small cell lung cancer (SCLC) is
detected in about 60% of the patients [3,4] while other tumors (thymoma,
lymphoma, leukemia, prostate cancer) are rarely diagnosed. Remission
of symptoms is rare in the SCLC-LEMS. In the non-tumor-LEMS (NTLEMS)
the prognosis is favorable [5] while in the tumor LEMS (T-LEMS)
it is related to tumor treatment [6].
Case Report
A 58 years old man, ex smoker, was referred for electrodiagnostic
consultation because of fluctuating proximal weakness for the last
6 months, dry mouth, sexual dysfunction and mild constipation.
Neurologic examination showed weakness of the proximal limb muscles
and absent tendon reflexes. Compound muscle action potential (CMAP)
from abductor digiti minimi (ADM) was 3.8 mV at rest and showed
increment 138% (9mV) immediately after 10 seconds of maximal muscle
contraction (Figure 1). Repetitive nerve stimulation (RNS) showed a
decrement of CMAP 24% at 3Hz and an increment 176% at 30Hz.With
the diagnosis of LEMS the patient was admitted to the hospital. SCLC
was diagnosed by Chest CT and biopsy (the patient had no symptoms of
SCLC). VGCC antibodies were positive. The patient was transferred to
an oncologic department and the tumor was treated with chemotherapy
and radiotherapy. Amifampridine 10 mg x3 was prescribed. When back
at home the patient felt well and referred no weakness. We saw him 3
months later. There was no muscle weakness and the tendon reflexes were
reduced. Amifampridine was withdrawn and a new electrophysiological
study was performed one week later. CMAP amplitude at rest from
ADM was 22 mV and RNS was normal and VGCC antibodies were not
found. On follow up, on July 2015, one and half year from amifampridine
withdrawal, the patient is still asymptomatic.
Discussion
LEMS is a presynaptic autoimmune or paraneoplastic neuromuscular
junction disorder. About 60% of patients with LEMS have a SCLC [4].
The syndrome is frequently misdiagnosed and the time to diagnosis is
0.6-40 months after the onset of the symptoms in the SCLC- LEMS [3].
Clinically it presents proximal muscle weakness, absent tendon reflexes
and autonomic symptoms mainly dry mouth, erectile dysfunction and
constipation. Electrophysiologically it is characterized by a triad of
findings: Low amplitude of compound muscle action potential (CMAP)
at rest, a decrement of CMAP amplitude at low rates (2-5 Hz) of repetitive
nerve stimulation (RNS), and an increment in CMAP amplitude (>100%)
at high rates of stimulation (30-50Hz) or after 10-15 seconds of maximal
voluntary contraction [7].Remission of symptoms is rare in the SCLCLEMS.
Chalk et al [6] reported neurological improvement in 7 of their 13
patients with SCLC and one showed complete remission for seven years.
There are also a few cases of LEMS associated with thymoma remitted
after successful treatment of the tumor [8,9].
Figure 1. A. RNS in ADM at diagnosis. B=Compound muscular
action potential (CMAP) from ADM at rest and after 10sec of muscular contraction at diagnosis. C= RNS in ADM after cancer treatment. D= CMAP from ADM after cancer treatment. ADM=Abductor digiti minimi, RNS= Repetitive nerve stimulation
Our patient presented a SCLC-LEMS diagnosed six months
from the onset of the symptoms and remitted completely (clinically,
electrophysiologically and serologically) after successful treatment of the
tumor. The remission of LEMS and the absence of VGCC antibodies after
SCLC treatment is a clear evidence of the paraneoplastic nature of the
disease. The reduction or removal of the antigen with the treatment of the
SCLC may improve or completely cure the LEMS [6].
Download Provisional PDF Here
Article Information
Article Type: Case Report
Citation: Zambelis T, Zouvelou V, Karandreas N
(2015) Complete Remission of Lambert-Eaton
Myasthenic Syndrome after Successful Treatment
of Small-Cell Lung Cancer. Autoimmun Infec Dis
1 (1): doi http://dx.doi.org/10.16966/2470-1025.105
Copyright: © 2015 Zambelis T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Publication history:
Received date: 20 July 2015
Accepted date: 25
August 2015
Published date: 30 August 2015